“The increase in research and development expenses was primarily due to increases related to clinical trial costs, preclinical research and development expenses and employee expenses (primarily due to an increase in personnel).”
“The decrease in the effective tax rate for fiscal 2025 was primarily due to the impact of the non-cash impairment charge and a more favorable geographic mix of earnings in the current year, partially offset by lower tax benefits recorded as excess tax deductions for stock compensation.”
“The increase in revenues was primarily due to acquisitions of $88.3 million, higher pricing of $49.4 million, and favorable impact of foreign currencies of $30.0 million, partially offset by lower organic volumes of $73.7 million.”